Studying the Clinical Trial Experiences of Patients With Mesothelioma

Status Not yet recruiting

Clinical Trial Summary

Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future mesothelioma patients during clinical trials.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05819580
Study type	Observational
Source	Power Life Sciences Inc.
Contact	Michael B Gill
Phone	415-900-4227
Email	bask@withpower.com
Status	Not yet recruiting
Phase
Start date	May 2024
Completion date	May 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01950572` - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Terminated	`NCT02838745` - Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Recruiting	`NCT01912547` - Thromboelastography During Surgery for Malignant Pleural Mesothelioma	Phase 0
Completed	`NCT01521325` - A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers	Phase 1
Recruiting	`NCT00996385` - Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Phase 2
Recruiting	`NCT02073500` - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed	`NCT02467426` - Isolated Thoracic Perfusion (ITP-F) for MPM	Phase 2
Completed	`NCT00407459` - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00787410` - An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma	Phase 2
Terminated	`NCT01907100` - Nintedanib (BIBF 1120) in Mesothelioma	Phase 2/Phase 3
Completed	`NCT04056026` - A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma	Early Phase 1
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03319537` - Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1